The company's sales accelerated through 2Q20 and grew in the high single digits in July, but it cautioned that the new patient pipeline could slow in 2H20.
The company exited 2Q20 with double-digit growth that accelerated to the mid-teens in July as new products and competitive rep hiring drove share gains.
A quicker than expected market recovery mitigated COVID's impact on the company's 2Q20 revenue as Zimmer Biomet shifts its focus to high-growth segments.
The company exited June 2020 with revenues up +42% compared to the prior year as it benefitted from a backlog of procedures rescheduled in March and April.
Sports medicine revenue from the acquisition of Parcus Medical and Arthrosurface helped Anika navigate the low point of the COVID orthopedic market in 2Q20.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more